LeMaitre Vascular (LMAT) Earnings Date & Reports

Key Takeaways

• LeMaitre Vascular reports third quarter 2026 results on Wednesday, November 4, 2026, after the market close.
• Company guidance calls for sales of $66.3 million to $68.3 million and earnings per share (EPS) of $0.66 to $0.71 for the quarter.
• Consensus estimates point to EPS of roughly $0.69 on revenue near $67 million, in line with the midpoint of management's guidance.
• A stronger U.S. dollar, Middle East export delays, and cardiac allograft supply constraints are expected to weigh on results.
• Investors will focus on Artegraft growth, gross margin, and any update to full-year 2026 guidance.

Earnings Context and Why It Matters

LeMaitre Vascular, a provider of vascular devices, implants, and services, enters its third quarter 2026 report at a pivotal moment. The company has posted four consecutive years of double-digit revenue growth, but recent quarters have been shaped by currency swings, regional export disruptions, and supply limitations in its tissue-based products. In the second quarter, organic sales rose 10%, yet results fell about $1.1 million short of guidance. Because this report will clarify whether those pressures are easing or persisting, it matters not only for the stock's near-term reaction but also for the credibility of the company's full-year outlook and its long-running Artegraft expansion story.

Earnings Expectations

For the third quarter of 2026, LeMaitre has guided to sales of $66.3 million to $68.3 million, representing roughly 10% reported growth and 11% organic growth at the midpoint. Management expects operating income of $17.3 million to $18.8 million and diluted EPS of $0.66 to $0.71. Wall Street consensus sits close to the midpoint, with analysts forecasting EPS of approximately $0.69 on revenue near $67 million.

A key nuance is the comparison to the prior-year quarter. Third quarter 2025 results included a one-time benefit from the Employee Retention Tax Credit, which inflated that period's reported EPS. Stripping out that item, the company's guidance implies about 11% adjusted EPS growth even as reported EPS is projected to decline roughly 9%. Investors should therefore watch both the headline figure and the underlying, adjusted performance.

Historically, LeMaitre has beaten consensus EPS in five of its last eight quarters, but it missed estimates in its most recent report, posting EPS of $0.74 against a $0.81 consensus. That miss contributed to a meaningful decline in the stock, raising the stakes for a cleaner quarter this time around.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, giving investors a data-driven way to monitor names like LeMaitre Vascular alongside the broader medical device sector. Explore the AI Screener to streamline your research and uncover actionable market insights.

Market Reaction and Investor Sentiment

Sentiment heading into this report is cautious. Since LeMaitre's August 4 earnings release, the stock has declined materially, reflecting investor unease about the combined impact of foreign exchange, export disruptions, and supply constraints that management flagged for the second half of 2026. The company's decision to trim its full-year organic revenue growth outlook from 12% to 11% further dampened enthusiasm.

Heading into the November 4 release, the market will be watching whether results land at, above, or below the guided midpoint, and whether management reaffirms or adjusts its full-year targets. Key risk factors include a further strengthening of the U.S. dollar, continued Middle East shipping disruptions, and slower-than-expected progress in resolving cardiac allograft supply limitations. Any commentary on Artegraft demand and international approvals will also influence sentiment.

Forward Outlook and Key Factors to Monitor

Following the earnings report, investors should focus on several themes that will shape LeMaitre's trajectory for the remainder of 2026 and into 2027. First, Artegraft remains the company's largest and fastest-growing product line, having grown 34% in the second quarter and represented 21% of total sales. Management expects roughly $11 million in Artegraft sales for 2026, and updates on international approvals, the Canadian launch, and demand for longer graft sizes will be closely watched.

Second, the currency environment matters. LeMaitre generates meaningful revenue in Europe and Asia-Pacific, so a stronger dollar can reduce reported growth even when underlying demand is solid. Investors should listen for how management frames foreign exchange assumptions for the fourth quarter.

Third, supply constraints in cardiac allografts and the lingering effect of prior catheter recall comparisons may continue to temper growth. Progress on tissue-processing capacity and any improvement in export conditions would be positive signals.

Finally, the company's gross margin expansion, operating margin, and sales force build-out toward 170 to 180 representatives by year-end will offer insight into profitability and future growth capacity. Full-year 2026 guidance currently implies 11% organic sales growth and roughly 21% EPS growth on an adjusted basis.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations